Hervé Hoppenot

Chairman, President and Chief Executive Officer

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015.

During Mr. Hoppenot’s tenure, the Company has tripled the number of clinical candidates in its portfolio, expanding beyond oncology to include research and development in inflammation & autoimmunity. Under his leadership, revenue has increased by over 400 percent, which includes the addition of two new revenue streams; and, with a goal to deliver medicines to patients worldwide, the Company has expanded geographically beyond the U.S. to include operations in 10 EU countries and Japan.

Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.

DASHYANT DHANAK, PHD

Executive Vice President and Chief Scientific Officer

Dash Dhanak joined Incyte in December of 2018 as Executive Vice President and Chief Scientific Officer. With 30 years of broad pharmaceutical and drug discovery experience, Dr. Dhanak joined Incyte from Janssen Research & Development, where, since 2013, he served as Vice President and Head of Discovery Sciences, leading the organization responsible for supporting and enabling the discovery and preclinical development of novel small molecule therapeutics. Prior to his tenure at Janssen, Dr. Dhanak spent 25 years at GlaxoSmithKline in positions of increased responsibility across multiple disease areas, including his last position as Vice President and Head of the Cancer Epigenetics Discovery Performance Unit.

Dr. Dhanak received a Bachelor of Science in Chemistry from the University of Manchester Institute of Science and Technology and his PhD from the University of London, both in the United Kingdom. He completed his postdoctoral research in natural product synthesis at Northwestern University in Chicago, Illinois.

JONATHAN E. DICKINSON

Senior Vice President, General Manager, Europe

Jonathan Dickinson joined Incyte as Senior Vice President and General Manager, Europe in June 2016. Mr. Dickinson joined Incyte from ARIAD Pharmaceuticals (Europe) Sàrl where he most recently held the position of Senior Vice President and General Manager, Europe. Prior to ARIAD, Mr. Dickinson served as European oncology brand lead at Bristol-Myers Squibb and before that, he held several key leadership positions, including lifecycle leader, during his 13-year tenure at Hoffmann-La Roche. At Roche, he had assignments both in the United States and Switzerland that included leadership roles for Roche’s three leading oncology medicines. Mr. Dickinson began his career at Novartis, where he held commercial roles in its oncology and endocrinology businesses, including medical sales, product manager and business director in the United Kingdom. Mr. Dickinson received his Bachelor of Science degree in Genetics and his MBA degree from the University of Nottingham.

LOTHAR H. FINKE, MD, PHD

Head of Clinical Development and General Manager, Japan

Lothar H. Finke joined Incyte in June 2017 as General Manager of Incyte Japan, establishing the Company’s corporate presence in Asia. Dr. Finke joined Incyte with over 20 years of biotech and pharmaceutical industry experience in roles of increasing responsibility at Merck KGaA, Argos Therapeutics, and Novartis Oncology with assignments in Europe, North America, and Asia. Prior to joining Incyte, Dr. Finke most recently led clinical development and medical affairs for Novartis Pharma KK’s oncology-hematology portfolio at their head office in Tokyo. Dr. Finke’s clinical background is in surgical oncology, having earned a medical degree and doctorate degree in cell biology from the University of Marburg, Germany.

BARRY P. FLANNELLY, PHARMD, MBA

Executive Vice President, General Manager, US

Barry Flannelly joined Incyte as Executive Vice President, Business Development and Strategic Planning in August 2014 and was appointed General Manager, US in June 2015. Dr. Flannelly has been working in oncology since 1987, and began his career in the pharmaceutical and biotech industry at Rhone-Poulenc Rorer, which later became Sanofi-Aventis. He has since had roles of increasing responsibility at Novartis Pharmaceuticals Corporation, Abraxis Oncology, Onyx Pharmaceuticals, Inc., and Nektar Therapeutics. During his career, he has held positions in medical affairs, strategic planning, and commercial operations, including head of sales, head of marketing, and business development. He earned his Doctor of Pharmacy from the University of Maryland School of Pharmacy, his Master in Business Administration from the University of Baltimore, and his Bachelor of Science in Pharmacy from Massachusetts College of Pharmacy.

VIJAY IYENGAR, MD

Executive Vice President, Global Strategy and Corporate Development

Vijay Iyengar joined Incyte in May 2016 as Executive Vice President, Global Strategy and Corporate Development leading the company’s Global Product Strategy, Business Development and Licensing, and Alliance Management teams. Dr. Iyengar has more than 13 years of pharmaceutical industry experience, most recently serving as the President of Genoptix Corporation, a Novartis Company. At Genoptix, he led a 650-person organization focused on delivering CAP/CLIA certified oncology diagnostic testing as well as providing clinical trial assay development and execution services. Previously, Dr. Iyengar held leadership roles in both U.S. and Global commercial functions at Novartis—he was Vice President and Rare Diseases Franchise Head at Novartis Oncology and Vice President and Oncology General Manager of Novartis Greece. Before joining Novartis in 2003, Dr. Iyengar was an Engagement Manager at McKinsey & Company where he served pharmaceutical and medical device clients as part of their healthcare practice. Dr. Iyengar received his Bachelor of Science degree in Biology from Stanford University and earned his MD from Harvard Medical School.

MICHAEL MORRISSEY

Corporate Senior Vice President, Head of Global Technical Operations

Michael Morrissey joined Incyte in January 2016 as Corporate Senior Vice President and Head of Global Technical Operations. He has more than 30 years of global pharmaceutical industry experience through his prior positions in Research and Development, Quality Assurance, and Manufacturing. Most recently, Mr. Morrissey served as Corporate Vice President, Head of International Technical Operations at Celgene International, where he built the company’s internal production and distribution capabilities and launched Celgene’s drugs worldwide. Prior to Celgene, he worked for Roche for 15 years in various positions. Mr. Morrissey holds a diploma in Physics and Applied Mathematics from the University of London, United Kingdom.

MARIA E. PASQUALE

Executive Vice President, General Counsel

Maria E. Pasquale joined Incyte in April of 2018 as Executive Vice President and General Counsel with nearly 20 years of legal, compliance, and intellectual property experience in the pharmaceutical industry. Ms. Pasquale joined Incyte from Celgene Corporation, where for 17 years she held positions of increasing levels of responsibility including Chief Counsel; Senior Vice President, Legal and Deputy General Counsel and Assistant Corporate Secretary, where she was responsible for overseeing and managing Global Legal Departments including Intellectual Property, Regulatory, Litigation, Investigations and Transactional matters for Celgene’s Corporate Headquarters and its over 50 wholly owned subsidiaries; and, most recently, Maria served as Celgene’s Executive Vice President and Global Chief Compliance Officer, responsible for GxP and Healthcare Compliance globally. Prior to her tenure at Celgene, Ms. Pasquale spent a decade supporting pharmaceutical clients as a global patent and litigation attorney at Pennie & Edmonds LLP in New York (now part of Jones Day). Before her career in law, Ms. Pasquale was an Assistant Research Scientist at the Institute for Basic Research and the Cold Spring Harbor Laboratory, where she designed and implemented research projects in the areas of Alzheimer’s Disease and oncology, respectively. Ms. Pasquale holds a Juris Doctor Degree from Brooklyn Law School and a Bachelor of Science degree in biochemistry from the State University of New York at Stony Brook.

CHRISTIANA STAMOULIS

Executive Vice President and Chief Financial Officer

Christiana Stamoulis joined Incyte as Executive Vice President and Chief Financial Officer in February 2019. With over 20 years of experience in the biotechnology industry, Ms. Stamoulis came to Incyte from Unum Therapeutics, where she was President and Chief Financial Officer. Prior to Unum, she was the Senior Vice President of Corporate Strategy and Business Development at Vertex Pharmaceuticals. Before joining Vertex, Ms. Stamoulis spent nearly 15 years in the investment banking and management consulting industries—she was a Managing Director at Citigroup’s Investment Banking division and previous to that a senior investment banker in the Healthcare Investment Banking Group at Goldman Sachs, where she spent the majority of her investment banking career. Ms. Stamoulis started her career as a strategy consultant at The Boston Consulting Group. Ms. Stamoulis holds two Bachelor of Science degrees from the Massachusetts Institute of Technology (MIT) and a Master of Business Administration degree from the MIT Sloan School of Management.

STEVEN H. STEIN, MD

Executive Vice President, Chief Medical Officer

Steven Stein joined Incyte as Senior Vice President and Chief Medical Officer in March 2015 and has over 10 years of experience in clinical development and regulatory interactions. Dr. Stein joined Incyte from Novartis Pharmaceuticals Corporation, where he most recently served as Senior Vice President, US Clinical Development & Medical Affairs at Novartis Oncology US. Dr. Stein previously worked at GlaxoSmithKline as Vice President, Global Oncology, Clinical Development and also as Head of Medicines Development for Hematology and Supportive Care. Dr. Stein earned his MD from the University of the Witwatersrand in Johannesburg, South Africa.

PAULA J. SWAIN

Executive Vice President, Human Resources

Paula Swain joined Incyte in January 2002 and serves as Executive Vice President of Human Resources. Before joining the company, Ms. Swain spent nearly 10 years with DuPont (acquired by Bristol-Myers Squibb Company in 2001), where she served as Vice President and Senior Vice President of Human Resources. She has also held human resource planning and employee relations positions with Chase Manhattan Bank, Marine Midland Bank, and Delaware Trust Company. Ms. Swain received her BA in psychology from Rockhurst College and graduated from the strategic human resources planning program at Harvard Business School.

WENQING YAO, PHD

Executive Vice President, Discovery Chemistry

Wenqing Yao joined Incyte in February 2002 as Director, Chemistry. Dr. Yao has more than 20 years of experience in medicinal chemistry. For the past nine years, Dr. Yao has held roles of increasing responsibility at Incyte, most recently as Senior Vice President, Discovery Chemistry. Before joining Incyte, Dr. Yao held scientific research positions with DuPont and Bristol-Myers Squibb Company from 1996 to 2002. Dr. Yao received his BS in chemistry from Xuzhou Normal University, his MS in organic chemistry from NanKai University, and his PhD in organic/medicinal chemistry from the University of Pennsylvania.